NFL: Why Sigyn Therapeutics Could Matter to NFL Players and Investors

In recent years, few issues have shaken professional football more than chronic traumatic encephalopathy (CTE) and traumatic brain injuries. Fans of the National Football League have watched former players struggle with memory loss, depression, and long-term neurological damage. It’s a crisis that has no true cure — until now.

​

A small, little-known company, Sigyn Therapeutics (OTCQB: SIGY), is developing a technology that could fundamentally change how these conditions are treated. And recent scientific discussion highlighted by Scientific American suggests the underlying approach is gaining serious attention.

​

The Big Idea: Cleaning the Blood to Help the Brain

At the center of Sigyn’s strategy is a technology called CardioDialysis™ — a device that works similarly to kidney dialysis.

Here’s the simple explanation:

• Blood is taken out of the body

• It passes through a special filtering system

• Harmful substances are removed

• Clean blood is returned to the body

 

This may sound simple, but the key is what gets removed.

Sigyn’s system is designed to eliminate:

• Inflammatory molecules

• Toxic proteins

• Disease-related particles circulating in the bloodstream

 

These substances are known drivers of disease progression.

​

Why This Matters for CTE and Brain Injuries

​

CTE and traumatic brain injuries are increasingly believed to be driven by inflammation in the brain.

 

After repeated hits:

• The brain releases inflammatory signals

• Toxic proteins build up

• Damage spreads over time

 

Here’s the critical insight:

 

Many of these harmful factors circulate in the blood before affecting the brain.

​

That’s where Sigyn’s approach becomes revolutionary.

​

Scientific discussion highlighted by Scientific American supports the idea that blood purification technologies could be used to treat neuroinflammatory diseases.

​

In plain English:

👉 If you can remove harmful inflammatory factors from the blood…
👉 You may be able to reduce damage happening in the brain

 

This opens the door to a completely new way of treating CTE — not with drugs, but with a device.

 

Why Drugs Haven’t Solved This Problem

For decades, medicine has tried to treat complex diseases with single-target drugs.

 

The problem?

• CTE and brain injuries involve many different damaging factors

• Drugs typically target just one pathway

 

Sigyn’s approach is different.

Instead of targeting one thing, it:

• Removes multiple harmful factors at once

• Works in real time

• Doesn’t rely on chemical interactions

 

This “multi-target” strategy is exactly why blood purification therapies have shown powerful results in other diseases.

 

Built on Existing Infrastructure — A Massive Advantage

​

One of the biggest hidden advantages of Sigyn’s technology is how easily it could scale.

 

There are already:

• Thousands of dialysis clinics in the U.S.

• Tens of thousands worldwide

 

Sigyn’s device is designed to plug into this existing system.

That means:

• No need to build new hospitals

• No complex distribution challenges

• Faster path to adoption if proven effective

 

For investors, this is a major strategic advantage.

 

Why This Could Be a Game-Changer for the NFL

 

Imagine this scenario:

 

An NFL player suffers repeated head impacts over a season.

Instead of waiting years for symptoms:

• They undergo periodic blood purification treatments

• Inflammation is reduced early

• Long-term damage may be limited

 

This could:

• Extend careers

• Improve post-retirement health

• Reduce liability concerns for the league

 

For fans, it means protecting the players they love.
For the league, it means protecting the future of the sport.

 

Potential for Accelerated Regulatory Path

 

Another critical factor that investors and fans should understand is the potential role of the U.S. Food and Drug Administration.

The health crisis surrounding brain injuries in the NFL is no longer a niche issue — it is a high-profile national concerninvolving player safety, long-term disability, and billions of dollars in liability.

Because of this, there is a strong argument that the FDA could accelerate the regulatory pathway for innovative treatments like Sigyn’s CardioDialysis™ technology.

 

Why?

• CTE and traumatic brain injury represent a massive unmet medical need

• There are currently no effective treatments or cures

• The issue directly impacts a major U.S. institution with enormous public visibility

• Pressure is increasing to find real solutions for player safety

 

The FDA has historically moved faster when:

• A condition is serious or life-threatening

• There are no adequate existing treatments

• A technology offers a fundamentally new approach

 

Sigyn’s strategy checks all three boxes.

 

If CardioDialysis™ demonstrates meaningful results, the FDA could consider:

• Fast Track designation

• Breakthrough Device designation

• Other accelerated review pathways

 

In simple terms:

👉 The bigger the problem…
👉 The more urgent the need…
👉 The faster regulators may move

 

And few problems today are bigger — or more visible — than brain injuries in professional football.

 

For investors, this matters enormously.

 

An accelerated pathway could mean:

• Faster clinical progress

• Earlier commercialization

• A shorter timeline to potential revenue

 

Why Investors Are Starting to Pay Attention

 

Sigyn Therapeutics is still a microcap — which is exactly why the opportunity could be significant.

 

Here’s what stands out:

​

1. Massive Addressable Market

• Brain injuries in sports

• Military traumatic brain injuries

• Neurodegenerative diseases

 

2. Unique Technology

• Device-based approach vs drugs

• Multi-target removal of disease drivers

 

3. Scientific Validation Momentum

• Recognition tied to Scientific American

• Expanding applications beyond cardiovascular disease

 

4. Platform Potential

The same technology could be used for:

• Heart disease

• Infections

• Cancer-related applications

 

The Bottom Line

 

CTE and traumatic brain injuries represent one of the biggest unsolved medical problems in sports — especially in the NFL.

For decades, there has been no true solution.

 

But Sigyn Therapeutics is pursuing a radically different approach:

Instead of trying to treat the damage… remove what causes the damage in the first place.

 

If successful, this could:

• Transform player health

• Change how brain injuries are treated

• Open a multi-billion-dollar market

 

For football fans, it offers hope.

 

For investors, it may represent early positioning in a breakthrough technology story.

And in the microcap world — those are exactly the moments that can lead to the biggest opportunities.

​

Legal Disclosures and Disclaimers

Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.

​

Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.

​

Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.

​

Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.

​

Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects’”, “will,” “anticipates,” “estimates,” “believes,” “understands” or that by statements indicating certain actions “may,” “could,” or “might” occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from.​ Green Planet Microcaps was compensated for this article and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap’s website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber’s inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.

​

Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber’s behalf under any circumstances.